◆英語タイトル:Altimmune Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8010849
◆発行会社(調査会社):
GlobalData
◆発行日:2017年12月20日
◆ページ数:29
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Altimmune Inc (Altimmune), formerly Vaxin Inc is a biotechnology company that develops vaccines and other biological products. The company’s products include novel vaccine delivery platforms, immunotherapeutic products, intranasally administered recombinant influenza vaccine, traditional influenza vaccines, anthrax vaccines, and immunotherapeutic product candidates. Its products are used in prevention and treatment of disease. Altimmune uses respirvec and densigen technologies for the development of vaccines. The company’s products are also used in the treatment of acute respiratory infections, chronic viral infections, and cancer. It has operation in London, UK and Strasbourg, France. Altimmune is headquartered in Gaithersburg, Maryland, the US.
Altimmune Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Altimmune Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Vaxin Raises USD16 Million in Venture Financing 10
Partnerships 11
Altimmune Enters into Contract Agreement with BARDA for NasoShield 11
Merger 12
Altimmune Merges with PharmAthene in Reverse Merger Transaction 12
Licensing Agreements 14
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 14
Equity Offering 15
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 15
Asset Transactions 17
WCCT Acquires Challenge Virus from Immune Targeting Systems 17
Acquisition 18
Vaxin Acquires Immune Targeting Systems 18
Altimmune Inc – Key Competitors 20
Altimmune Inc – Key Employees 21
Altimmune Inc – Locations And Subsidiaries 22
Head Office 22
Other Locations & Subsidiaries 22
Recent Developments 23
Financial Announcements 23
Nov 09, 2017: Altimmune Announces Third Quarter 2017 Financial Results and Provides Corporate Update 23
Aug 10, 2017: Altimmune Announces Second Quarter 2017 Financial Results and Provides Corporate Update 25
Corporate Communications 26
May 16, 2017: Altimmune Promotes Dr. Sybil Tasker to Chief Medical Officer 26
Sep 13, 2016: Altimmune Announces Addition of Christine Brennan to Board of Directors 27
Product News 28
08/05/2016: PharmAthene Files Protest Against HHS Over Anthrax Vaccine Bidding Process 28
Appendix 29
Methodology 29
About GlobalData 29
Contact Us 29
Disclaimer 29
List of Tables
Altimmune Inc, Pharmaceuticals & Healthcare, Key Facts 2
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Altimmune Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Altimmune Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Altimmune Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Altimmune Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Vaxin Raises USD16 Million in Venture Financing 10
Altimmune Enters into Contract Agreement with BARDA for NasoShield 11
Altimmune Merges with PharmAthene in Reverse Merger Transaction 12
Valneva Enters into Licensing Agreement with Immune Targeting Systems for IC31 Adjuvant 14
Altimmune Raises USD14.7 Million in Private Placement of Series B Preferred Shares 15
WCCT Acquires Challenge Virus from Immune Targeting Systems 17
Vaxin Acquires Immune Targeting Systems 18
Altimmune Inc, Key Competitors 20
Altimmune Inc, Key Employees 21
Altimmune Inc, Subsidiaries 22